<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-610" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mechanical Aortic Valve Replacement</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gopal</surname>
            <given-names>Shwetha</given-names>
          </name>
          <aff>Bassett Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hauser</surname>
            <given-names>Joshua M.</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahboobi</surname>
            <given-names>Sohail K.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shwetha Gopal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Hauser declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sohail Mahboobi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-610.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Mechanical aortic valve replacement (MAVR) is a vital surgical intervention for patients with severe aortic valve disease, such as aortic stenosis or regurgitation, where the native valve's function is compromised. The procedure involves the implantation of a mechanical prosthetic valve that mimics the function of the natural valve while offering superior durability compared to bioprosthetic valves. Mechanical valves, known for their longevity&#x02014;often lasting over 20 years&#x02014;are particularly beneficial for younger patients or those who can tolerate lifelong anticoagulation therapy, which is necessary to prevent thromboembolic complications. Despite the advantages, the need for continuous anticoagulation presents challenges, including an increased risk of bleeding, making careful patient selection and ongoing management critical.</p>
        <p>Participants in this course gain a thorough understanding of the comprehensive care required for patients undergoing MAVR, from preoperative evaluation and patient selection to the intricacies of surgical techniques and the management of anticoagulation therapy. The course emphasizes the importance of collaborating with an interprofessional team, which plays a crucial role in optimizing patient outcomes. Through coordinated care, including regular monitoring, patient education, and timely interventions, the interprofessional team ensures that patients receive the best possible care, thereby reducing the risk of complications and enhancing the overall success of the procedure.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify candidates most suitable for mechanical aortic valve replacement based on clinical indications and patient characteristics.</p></list-item><list-item><p>Differentiate between mechanical and biological valve options, considering patient-specific factors and long-term management needs.</p></list-item><list-item><p>Implement evidence-based strategies for perioperative care and long-term anticoagulation management&#x000a0;after mechanical aortic valve replacement.</p></list-item><list-item><p>Collaborate with a multidisciplinary team to optimize perioperative and postoperative care, enhancing patient outcomes after mechanical aortic valve replacement.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=610&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=610">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-610.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Mechanical aortic valve replacement (MAVR) is a critical intervention for patients with severe aortic valve disease compromising valvular functionality, including aortic stenosis and regurgitation. The procedure involves the surgical implantation of a mechanical prosthetic valve designed to replicate the native valve's function while offering durability that often surpasses that of bioprosthetic valves; mechanical valves can last for approximately 20 years.<xref ref-type="bibr" rid="article-610.r1">[1]</xref><xref ref-type="bibr" rid="article-610.r2">[2]</xref> Since the first successful aortic valve replacement in the 1960s, significant advancements have been made in valve design, surgical techniques, and perioperative care, contributing to improved patient outcomes.</p>
        <p>Mechanical valves are favored in certain patient populations due to their long-term durability. They often outlast biological valves, which tend to degrade over time. Patients, especially younger individuals or those without contraindications to lifelong anticoagulation therapy, may benefit from the durability of a mechanical valve, reducing the likelihood of reoperation. However, the requirement for lifelong anticoagulation presents unique challenges, as it increases the risk of bleeding complications. This activity for healthcare professionals reviews the indications, patient selection, surgical techniques, anticoagulation management, and long-term outcomes of MAVR and highlights the role of the interprofessional team in improving outcomes for patients who undergo this procedure.</p>
      </sec>
      <sec id="article-610.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>MAVR is a surgical procedure that replaces a diseased or malfunctioning aortic valve with a mechanical prosthesis. The success of this procedure depends on a deep understanding of the intricate anatomy of the aortic valve and heart.&#x000a0;</p>
        <p>
<bold>Aortic Valve</bold>
</p>
        <p>The aortic valve lies between the left ventricle and the aorta, regulating blood flow from the heart to the systemic circulation. Usually, the aortic valve consists of&#x000a0;3 cusps&#x02014;the right coronary cusp (RCC), left coronary cusp (LCC), and noncoronary cusp (NCC). These cusps open during systole to allow blood flow into the aorta and close during diastole to prevent backflow into the left ventricle. In adults, the normal aortic valve area is 3 to 4 cm<sup>2</sup>.&#x000a0;Anatomical variants such as the bicuspid aortic valve present in 1% to 2% of the population can complicate MAVR procedures.<xref ref-type="bibr" rid="article-610.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>Leaflets (Cusps)</bold>
</p>
        <p>The leaflets, or cusps, are the valve's primary sealing mechanism, forming the boundary between the left ventricle and the aorta, ensuring efficient blood flow during systole, and preventing regurgitation during diastole. In a trileaflet valve, the NCC is usually the largest leaflet, handling most of the systolic flow. The leaflets have fibrous surfaces known as lunulae, which are crucial for their coaptation. A nodule of Arantius, thickening at the center of the leaflet edges, ensures the valve's competence during closure. The leaflets also form a spherical shape with the aortic walls, creating the sinuses of Valsalva, which are key to maintaining valve function and coronary blood flow. The LCC covers the left coronary sinus and the origin of the left main coronary artery, the&#x000a0;RCC covers the right coronary sinus and the origin of the right coronary artery, and the&#x000a0;NCC covers the noncoronary sinus towards the interatrial septum.<xref ref-type="bibr" rid="article-610.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>Annulus</bold>
</p>
        <p>The annulus is a circular, fibrous ring that forms the foundation of the aortic valve. This structure anchors the valve cusps and provides the necessary stability for valve function. During MAVR, the mechanical prosthesis is anchored to this annular base. The annulus represents the boundary where the aortic valve leaflets are attached and is crucial for determining the size and position of the prosthesis. Echocardiography and imaging techniques measure the annulus to guide prosthesis sizing in surgical aortic valve replacement and transcatheter aortic valve&#x000a0;replacement. The annulus marks the smallest orifice through which blood is ejected from the left ventricle, highlighting its importance in maintaining effective cardiac output.</p>
        <p>
<bold>Sinuses of Valsalva</bold>
</p>
        <p>The sinuses of Valsalva are&#x000a0;3 dilated pockets in the aortic root, located just above the valve cusps. These sinuses play a critical role in coronary blood flow and valve function. The right and left sinuses contain the origins of the right and left coronary arteries, while the noncoronary sinus does not house a coronary artery. The sinuses extend from the leaflet insertions to the sinotubular junction (STJ) and are essential for ensuring proper valve closure and preventing the cusps from sticking to the aortic wall. The walls of these sinuses are composed of thin aortic tissue, with the base containing varying amounts of ventricular tissue. The sinuses allow for the efficient closure of the valve and contribute to coronary perfusion during diastole.</p>
        <p>
<bold>Commissures</bold>
</p>
        <p>Commissures are where the valve cusps attach to the aortic wall, forming a crown-like structure critical for the valve's stability and function. The commissures are typically located at or slightly below the STJ. The areas beneath the commissures, known as interleaflet triangles, consist of fibrous or muscular tissue. These structures contribute to the valve's structural integrity and proper coaptation, ensuring one-way blood flow. The interleaflet triangle between the NCC and LCC is continuous with the anterior mitral leaflet, forming the aortomitral curtain. In contrast, the triangle between the NCC and RCC is continuous with the membranous interventricular septum, where surgical incisions can disrupt the heart's conduction system and cause arrhythmias.</p>
        <p>
<bold>Sinotubular Junction</bold>
</p>
        <p>The STJ is a noncircular, scalloped structure marking the boundary between the aortic root and the ascending aorta&#x000a0;that is vital in maintaining the geometry of the valve cusps and the valve's overall function. The coronary ostia, openings for the coronary arteries, are typically located just below this junction. During MAVR, avoiding interference with the normal function of the valve and the coronary arteries when placing the prosthesis is crucial.</p>
        <p>
<bold>Left Ventricle</bold>
</p>
        <p>The heart's main pumping chamber is the left ventricle, pushing oxygenated blood into the aorta through the aortic valve. The relationship between the aortic valve and the left ventricular outflow tract is crucial in MAVR. The alignment and positioning of the mechanical valve are critical to maintaining efficient blood flow and minimizing the risk of complications such as left ventricular outflow obstruction.</p>
        <p>
<bold>Ascending Aorta and Coronary Arteries</bold>
</p>
        <p>The ascending aorta begins immediately after the aortic valve and carries oxygenated blood to the rest of the body. The right and left coronary arteries originate from the sinuses of Valsalva and provide blood supply to the heart muscle. During MAVR, it is essential to avoid obstructing these arteries to ensure adequate blood flow to the myocardium.</p>
      </sec>
      <sec id="article-610.s4" sec-type="Indications">
        <title>Indications</title>
        <p>MAVR is a surgical procedure indicated for patients with aortic valve disease when the native valve is severely dysfunctional and requires replacement.&#x000a0;The incidence of aortic valve disease increases with age;&#x000a0;1 in&#x000a0;8 people aged 75 and older have moderate to severe valvular heart disease.<xref ref-type="bibr" rid="article-610.r5">[5]</xref> The primary conditions warranting MAVR include aortic stenosis, aortic regurgitation, and some cases of complex congenital heart disease. The choice of a mechanical valve is influenced by patient-specific factors such as age, life expectancy, the need for long-term anticoagulation, and lifestyle. Indications for MAVR are varied (and include but are not necessarily limited to) aortic stenosis, aortic regurgitation, or a congenital bicuspid aortic valve&#x02014;as part of a comprehensive repair for congenital cardiac disease, or when reoperation for a failed bioprosthetic valve is required.&#x000a0;</p>
        <p>
<bold>Aortic Stenosis</bold>
</p>
        <p>Aortic stenosis is a potentially serious condition that affects blood flow from the heart to the rest of the body. Calcification and atherosclerosis of the valve are the most common causes of aortic stenosis.<xref ref-type="bibr" rid="article-610.r6">[6]</xref>&#x000a0;Aortic stenosis&#x000a0;is the most common type of valvular heart disease in older adults. The natural history of aortic stenosis usually begins with an asymptomatic period, with symptoms having developed once the valve is critically stenosed. The progression of the stenotic valve and timing of symptom onset varies from patient to patient.&#x000a0;Symptomatic individuals with severe stenosis have a poor prognosis. Ross first described the higher mortality rate after the onset of cardiac symptoms in 1968.<xref ref-type="bibr" rid="article-610.r7">[7]</xref>&#x000a0;</p>
        <p><bold>Asymptomatic severe aortic stenosis:</bold> MAVR may be considered in asymptomatic individuals with severe aortic stenosis if there is evidence of left ventricular dysfunction, very high gradients, or rapid progression of stenosis.</p>
        <p><bold>Severe aortic stenosis:</bold> The most common indication for MAVR is severe aortic stenosis, characterized by significant narrowing of the aortic valve, which restricts blood flow from the left ventricle to the aorta. Patients typically present with symptoms such as chest pain, shortness of breath, syncope, or heart failure.&#x000a0;Over the past 6 decades,&#x000a0;SAVR has become a gold&#x000a0;standard for patients who are high-risk.<xref ref-type="bibr" rid="article-610.r8">[8]</xref>&#x000a0;Indications for aortic valve replacement have changed tremendously. Results from a series of landmark clinical trials have shown a beneficial effect in those who are intermediate- to low-risk.<xref ref-type="bibr" rid="article-610.r9">[9]</xref>&#x000a0;Surgical valve replacement is indicated when symptoms are present, or the left ventricular function is compromised. Transthoracic (TTE) and transesophageal echocardiography (TEE) are the best tools for evaluating aortic valve morphology. The American Society of Echocardiography outlines strict criteria for severe aortic stenosis and the need for aortic valve replacement. Severe aortic stenosis is described as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aortic valve area of less than or equal to 1.0 cm<sup>2</sup></p>
          </list-item>
          <list-item>
            <p>Mean transvalvular aortic gradient greater or equal to 40 mm Hg</p>
          </list-item>
          <list-item>
            <p>The maximum aortic jet velocity is greater than or equal to 4 m/s across the valve&#x000a0;<xref ref-type="bibr" rid="article-610.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>The stages and recommendations for aortic valve replacement in patients with valvular stenosis are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe high-gradient aortic stenosis&#x000a0;with symptoms by either history or exercise testing (stage D1)</p>
          </list-item>
          <list-item>
            <p>Asymptomatic with severe&#x000a0;stenosis (stage C2) and left ventricular ejection fraction &#x0003c;50 %&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe&#x000a0;stenosis (stage C or D) undergoing other cardiac surgery&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Asymptomatic with severe&#x000a0;stenosis and low surgical risk</p>
          </list-item>
          <list-item>
            <p>Asymptomatic with severe&#x000a0;stenosis and decreased exercise tolerance or fall in systemic blood pressure&#x000a0;<xref ref-type="bibr" rid="article-610.r11">[11]</xref><xref ref-type="bibr" rid="article-610.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Aortic Regurgitation</bold>
</p>
        <p>Individuals with mild to moderate aortic regurgitation typically remain asymptomatic, with a minimal risk of adverse events. Continuous monitoring of patients with chronic aortic regurgitation through clinical assessments and echocardiography is imperative, focusing on symptom changes, regurgitation severity, and&#x000a0;left ventricular systolic dysfunction.</p>
        <p><bold>Acute aortic regurgitation:</bold> MAVR is also indicated in cases of acute aortic regurgitation, often due to endocarditis, aortic dissection, or trauma. The sudden onset of severe regurgitation can rapidly lead to hemodynamic instability and necessitates urgent surgical intervention.</p>
        <p><bold>Severe aortic regurgitation:</bold> MAVR is indicated in patients with severe aortic regurgitation, where the aortic valve fails to close properly, causing blood to leak back into the left ventricle during diastole. This condition can lead to left ventricular dilation, hypertrophy, and eventually heart failure. MAVR is recommended in symptomatic individuals or those with evidence of left ventricular dysfunction (ejection fraction &#x0003c;50%) or significant dilation.</p>
        <p>Severe aortic regurgitation is quantified as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vena contracta &#x02265;0.6 cm</p>
          </list-item>
          <list-item>
            <p>Holodiastolic reversal of blood flow</p>
          </list-item>
          <list-item>
            <p>Regurgita</p>
          </list-item>
          <list-item>
            <p>Regurgitant fraction&#x000a0;&#x02265;50%</p>
          </list-item>
          <list-item>
            <p>Effective regurgitant orifice&#x000a0;&#x02265;0.3 cm<sup>2&#x000a0;</sup></p>
          </list-item>
        </list>
        <p>The American Heart Association&#x000a0;class I indications for aortic valve replacement in patients with aortic regurgitation are:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptomatic with severe aortic regurgitation</p>
          </list-item>
          <list-item>
            <p>Asymptomatic with severe aortic regurgitation and an ejection fraction&#x000a0;&#x02264;55%</p>
          </list-item>
          <list-item>
            <p>Asymptomatic, undergoing other cardiac surgery&#x000a0;<xref ref-type="bibr" rid="article-610.r13">[13]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Congenital Aortic Valve Disease</bold>
</p>
        <p><bold>Bicuspid aortic valve:</bold> Patients with bicuspid aortic valve disease may develop significant aortic stenosis or regurgitation over time, requiring MAVR. The decision to opt for a mechanical valve is based on the patient's age, the need for reoperation, and life expectancy.</p>
        <p><bold>Complex congenital heart defects:</bold> In some patients with complex congenital heart conditions, MAVR may be required as part of a broader surgical repair or reconstruction strategy.</p>
        <p>
<bold>Reoperation for Failed Bioprosthetic Valve</bold>
</p>
        <p><bold>Structural valve deterioration:</bold> In younger patients or those with a history of failed bioprosthetic valves due to structural valve deterioration, MAVR may be preferred as mechanical valves offer greater durability and reduce the likelihood of future reoperations.</p>
        <p>
<bold>Patient Selection Criteria</bold>
</p>
        <p>Several factors influence the selection of a mechanical valve over a bioprosthetic valve:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age and life expectancy: Mechanical valves are preferred in younger patients due to their durability and long lifespan. For patients 60 and older, the longevity of a mechanical valve outweighs the need for long-term anticoagulation.</p>
          </list-item>
          <list-item>
            <p>Anticoagulation tolerance: Since mechanical valves require lifelong anticoagulation with warfarin to prevent thromboembolism, patient compliance and the ability to manage anticoagulation therapy are crucial considerations.</p>
          </list-item>
          <list-item>
            <p>Lifestyle considerations: Patients with active lifestyles or those at high risk for reoperation may benefit from the durability of a mechanical valve despite the need for anticoagulation.</p>
          </list-item>
        </list>
        <p>A mechanical valve is preferable over a bioprosthetic valve in the following patients:</p>
        <list list-type="bullet">
          <list-item>
            <p>Surgical aortic valve replacement in patients aged &#x0003c;55</p>
          </list-item>
          <list-item>
            <p>No contraindication to anticoagulation with vitamin K antagonist</p>
          </list-item>
          <list-item>
            <p>An existing indication for anticoagulation, like a prosthetic mechanical valve at a different location</p>
          </list-item>
          <list-item>
            <p>High risk of morbidity and mortality with the intervention&#x000a0;<xref ref-type="bibr" rid="article-610.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>The following are predictors of poor outcomes in patients undergoing aortic valve replacement:</p>
        <list list-type="bullet">
          <list-item>
            <p>Concomitant cardiac diseases: These can further compromise myocardial function, such as poor left ventricular ejection fraction, previous cardiac surgery, and associated coronary artery disease.</p>
          </list-item>
          <list-item>
            <p>Neurological dysfunction</p>
          </list-item>
          <list-item>
            <p>Chronic lung disease or terminal end-organ lung dysfunction</p>
          </list-item>
          <list-item>
            <p>Liver cirrhosis or terminal end-organ liver dysfunction</p>
          </list-item>
          <list-item>
            <p>Renal insufficiency</p>
          </list-item>
          <list-item>
            <p>Recent&#x000a0;stroke within the last&#x000a0;6 months</p>
          </list-item>
          <list-item>
            <p>Severe pulmonary hypertension with right ventricular dysfunction</p>
          </list-item>
          <list-item>
            <p>Echocardiographic evidence of an intracardiac mass, thrombus, or vegetation</p>
          </list-item>
          <list-item>
            <p>Life expectancy of less than 12 months owing to a noncardiac cause</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction within the last 30 days&#x000a0;<xref ref-type="bibr" rid="article-610.r15">[15]</xref><xref ref-type="bibr" rid="article-610.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-610.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>MAVR is a critical intervention for patients with severe aortic valve disease, but it is not suitable for everyone. Contraindications to MAVR can be absolute or relative and often involve patient-specific factors that increase the risk of poor outcomes or complications. The key contraindications are:</p>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <p><bold>Inability to adhere to anticoagulation therapy:</bold> MAVR requires lifelong anticoagulation with medications like warfarin to prevent thromboembolic events. Patients who are unable or unwilling to comply with anticoagulation therapy or who have a history of nonadherence are at high risk for valve thrombosis and embolic events. A bioprosthetic valve, which generally does not require long-term anticoagulation, may be more appropriate for these patients.</p>
        <p><bold>Active infection:</bold> Patients with active endocarditis or other systemic infections are contraindicated for MAVR until the infection is fully treated. Placing a prosthetic valve in the presence of an active infection significantly increases the risk of prosthetic valve endocarditis, which can be life-threatening.</p>
        <p><bold>Severe bleeding disorders:</bold> Patients with conditions that predispose them to bleeding, such as hemophilia, severe thrombocytopenia, or other coagulopathies, may not be suitable candidates for MAVR due to the need for long-term anticoagulation. The risk of life-threatening bleeding complications outweighs the benefits of the procedure in these cases.</p>
        <p>
<bold>Relative Contraindications</bold>
</p>
        <p><bold>Advanced age or frailty:</bold> While age alone is not an absolute contraindication, patients who are at an advanced age or frail may not tolerate the anticoagulation therapy required after MAVR or may have a limited life expectancy, making the procedure's risks outweigh its potential benefits; in such cases, a bioprosthetic valve might be preferred.</p>
        <p><bold>Severe comorbidities:</bold> Patients with significant comorbidities, such as advanced chronic kidney disease, liver disease, or pulmonary hypertension, may have a higher risk of complications from the surgery and the required anticoagulation. These conditions may tilt the balance toward opting for a bioprosthetic valve or even nonsurgical management.</p>
        <p><bold>Pregnancy or desire for future pregnancy:</bold> Warfarin, the anticoagulant commonly used after MAVR, is teratogenic and poses significant risks during pregnancy. Women of childbearing age who desire pregnancy may be better candidates for a bioprosthetic valve, which requires shorter-term or no anticoagulation, reducing the risks associated with pregnancy.</p>
        <p><bold>History of thromboembolism despite adequate anticoagulation:</bold> Patients who have experienced thromboembolic events while on therapeutic anticoagulation present a challenging situation. The risk of recurrent embolic events with a mechanical valve may be deemed too high, necessitating consideration of alternative treatments.</p>
      </sec>
      <sec id="article-610.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>The following equipment is required for the MAVR procedure:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiopulmonary bypass machine</p>
          </list-item>
          <list-item>
            <p>The valve prostheses of various sizes</p>
          </list-item>
          <list-item>
            <p>Transesophageal echocardiography</p>
          </list-item>
          <list-item>
            <p>Surgical instruments</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-610.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>An interprofessional heart team evaluates and prepares the patient for the procedure.&#x000a0;</p>
        <p>The heart team includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiologist and interventional cardiologist</p>
          </list-item>
          <list-item>
            <p>Cardiothoracic surgeons</p>
          </list-item>
          <list-item>
            <p>Cardiac anesthesiologist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nurses</p>
          </list-item>
          <list-item>
            <p>Coordinator</p>
          </list-item>
          <list-item>
            <p>Intensivist</p>
          </list-item>
        </list>
        <p>The following staff is needed to carry out aortic valve replacement:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiothoracic surgeon</p>
          </list-item>
          <list-item>
            <p>Cardiac anesthesiologist</p>
          </list-item>
          <list-item>
            <p>Perfusionist</p>
          </list-item>
          <list-item>
            <p>Nurses</p>
          </list-item>
          <list-item>
            <p>Industry representative (for newer valves)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-610.s8" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>
<bold>Aortic Valve Replacement Methods</bold>
</p>
        <p>Aortic valve replacement&#x000a0;has been shown to substantially improve survival in patients with symptomatic severe aortic disease, which has formed the basis for recommending this procedure in such circumstances.<xref ref-type="bibr" rid="article-610.r17">[17]</xref>&#x000a0;Currently, 2 techniques are being used for aortic valve replacement: the surgical aortic valve replacement, SAVR, and the TAVR approaches. TAVR is the minimally invasive surgical&#x000a0;technique for aortic valve replacement for&#x000a0;patients who are not candidates for SAVR.</p>
        <p>Surgical aortic valve replacement can be performed via the following methods:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Minimally invasive&#x000a0;SAVR</p>
          </list-item>
          <list-item>
            <p>Right anterior minithoracotomy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ministernotomy</p>
          </list-item>
          <list-item>
            <p>Conventional sternotomy and valve replacement&#x000a0;<xref ref-type="bibr" rid="article-610.r18">[18]</xref><xref ref-type="bibr" rid="article-610.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>Transcatheter aortic valve replacement can be performed&#x000a0;using the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Two United States Food and Drug Administration-approved valves are available:
<list list-type="bullet"><list-item><p>SAPIEN valves (Edwards Lifesciences)&#x000a0;</p></list-item><list-item><p>CORE-valves (Medtronic): The newest generation Medtronic valve is the EVOLUTE-R, which can self-expand and reposition after deployment.<xref ref-type="bibr" rid="article-610.r20">[20]</xref>&#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Valve Types</bold>
</p>
        <p>The&#x000a0;3 primary types of artificial heart valves are mechanical, bioprosthetic, and tissue-engineered. Mechanical valves are made from strong, durable materials. Bioprosthetic valves are derived from animal tissue (porcine valves) or flexible material like bovine pericardium. Tissue-engineered valves are cultivated in vitro by seeding human cells onto a scaffold. This activity focuses on mechanical heart valves, of which there are 3 types:</p>
        <p><bold>Caged ball valve:&#x000a0;</bold>The first artificial heart valve featured a metal cage with a silicone elastomer ball. As the heart contracts and chamber pressure exceeds that of the atrium, the ball rises, blocking blood flow. When pressure drops, the ball falls, allowing blood flow. Due to a high risk of clotting and adverse hemodynamic effects, caged ball valves are no longer used.</p>
        <p><bold>Tilting disc valve:&#x000a0;</bold>This valve features a metal ring holding a disc covered by fabric for suturing. When chamber pressure drops, the valve opens to allow blood flow and closes to prevent backflow. The Medtronic-Hall model is the most widely used tilting disc design in the United States.</p>
        <p><bold>Bileaflet valve:&#x000a0;</bold>The most common mechanical valve prosthesis consists of&#x000a0;2 semicircular leaflets.&#x000a0;This valve&#x000a0;is the least thrombogenic among mechanical valves and is characterized by its washing regurgitant blood jets.<xref ref-type="bibr" rid="article-610.r21">[21]</xref></p>
        <p>
<bold>Procedural&#x000a0;Techniques</bold>
</p>
        <p>MAVR is a sophisticated procedure aimed at addressing severe aortic valve disease. The choice between SAVR and TAVR depends on patient-specific factors, including their overall health and suitability for surgery.</p>
        <p>
<bold>Surgical Aortic Valve Replacement</bold>
</p>
        <p>SAVR is performed through a median sternotomy, where the chest is opened to access the heart. After opening the pericardium, cardiopulmonary bypass is established using cannulation of the aorta and venous system to manage circulation during surgery. A left ventricular vent is inserted to maintain a dry field, typically through the right superior pulmonary vein, left atrium, or mitral valve.</p>
        <p>The next step involves cooling the patient to a bladder temperature of 32 &#x000b0;C. The aorta is then cross-clamped, and cardioplegia is administered through either a retrograde coronary sinus catheter or an antegrade cannula in the aortic root to arrest the heart and protect the myocardium. If there is aortic valve regurgitation, cardioplegia may be directly administered into the coronary ostia to prevent left ventricular dilation.</p>
        <p>A hockey stick incision is made in the aorta, extending up to the noncoronary sinus of Valsalva, just above the aortic annulus. The valve leaflets are excised starting at the commissure between the right and noncoronary sinus. Calcifications are removed with a Rongeur, and the left ventricle is flushed and suctioned to eliminate debris, which could lead to complications such as stroke.</p>
        <p>The annulus is measured using a sizer to select the appropriate prosthetic valve size. The new valve is attached to the annulus with pledgeted or nonpledgeted sutures. Pledgeted sutures are used for friable annuli and are placed in a horizontal mattress fashion, while nonpledgeted sutures may be used in horizontal mattresses or interrupted patterns. Suturing begins at the commissure between the left and right coronary cusps, proceeding in a specific order to avoid damaging the conduction tissue.</p>
        <p>Once all sutures are in place and the prosthesis is positioned supraannularly, the aorta is closed with 4-0 polypropylene sutures in&#x000a0;2 layers. If needed, a patch enlargement using pericardial or Dacron material may be performed to reduce tension on the suture line. Strong suction is applied to the cardioplegia cannula postclosure for de-airing, and the aortic cross-clamp is released. Transesophageal echocardiography&#x000a0;is used to ensure there is no residual air and that the valve functions correctly.</p>
        <p>
<bold>Transcatheter Aortic Valve Replacement</bold>
</p>
        <p>TAVR is most commonly performed via the transfemoral approach, where the catheter is inserted through the femoral artery in the groin. Depending on the patient's anatomy, alternative access routes include the transapical (through the chest wall) or transaortic (through a small incision in the chest) approaches. The procedure begins with a balloon valvuloplasty, where a balloon is inflated inside the narrowed aortic valve to widen the valve opening; this prepares the site for the new valve.</p>
        <p>The new valve is crimped onto a balloon or self-expanding stent and delivered via the catheter to the aortic valve site. The balloon is inflated, or the stent is expanded, positioning the new valve within the diseased valve, which remains in place and holds the new valve in position. The valve is carefully positioned, and its function is checked using imaging techniques like fluoroscopy and echocardiography. Adjustments may be made to ensure optimal placement. Once the valve is seated correctly and functioning, the delivery system is removed. Hemostasis is achieved at the access site, and the procedure is concluded.</p>
      </sec>
      <sec id="article-610.s9" sec-type="Complications">
        <title>Complications</title>
        <p>MAVR is a life-saving procedure for patients with severe aortic valve disease, but it carries a range of potential complications that must be carefully managed. These complications can be categorized into immediate postoperative, long-term, and anticoagulation-related issues.</p>
        <p>
<bold>Immediate Postoperative Complications</bold>
</p>
        <p><bold>Bleeding:</bold> This is the most common complication due to the need for anticoagulation. Postoperative bleeding may require reoperation and is a major cause of early morbidity.</p>
        <p><bold>Thromboembolism:</bold> Despite anticoagulation, thrombus formation can occur on the mechanical valve, leading to embolic events such as stroke or systemic embolism. Mechanical aortic valves are more&#x000a0;prone to thromboembolic complications compared to bioprosthetic valves (1%-2% vs 0.7%) and bleeding complications&#x000a0;due to&#x000a0;the requirement of long-term anticoagulation to avoid thromboembolic events, eg stroke, acute leg ischemia, or visceral embolization.</p>
        <p><bold>Paravalvular leak:</bold> A small amount of blood can flow around the valve between the sewing ring and the native tissue, leading to a paravalvular leak. If severe, this can result in hemolysis, heart failure, or the need for reoperation.</p>
        <p><bold>Infection:</bold> Prosthetic valve endocarditis is a serious complication that can occur early or late after MAVR, requiring prompt antibiotic therapy and may necessitate reoperation.</p>
        <p>
<bold>Long-Term Complications</bold>
</p>
        <p><bold>Structural deterioration:</bold> Unlike bioprosthetic valves, mechanical valves are designed to last a lifetime. However, mechanical parts can wear out over time, leading to valve malfunction&#x02014;though this is rare.</p>
        <p><bold>Valve thrombosis:</bold> Mechanical valves are prone to thrombosis, particularly if anticoagulation levels are subtherapeutic. Valve thrombosis can lead to acute valve obstruction, which is a surgical emergency.</p>
        <p><bold>Hemolysis:</bold> Blood cells can be damaged as they pass through the mechanical valve, leading to hemolytic anemia. Mild hemolysis is common, but severe cases may require additional interventions. Blood work usually reveals anemia in patients with mechanical aortic valves.<xref ref-type="bibr" rid="article-610.r22">[22]</xref></p>
        <p><bold>Anticoagulation-related complications:</bold> Lifelong anticoagulation with warfarin or other agents is required to prevent thromboembolism. However, this increases the risk of bleeding complications, including intracranial hemorrhage, gastrointestinal bleeding, and other bleeding events. Maintaining a balance between preventing clotting and avoiding excessive bleeding is a significant challenge.</p>
        <p>
<bold>Anticoagulation Management Challenges</bold>
</p>
        <p><bold>International normalized ratio monitoring:</bold> Patients with mechanical valves need regular monitoring of their international normalized ratio (INR) to ensure that anticoagulation is within the therapeutic range (usually INR 2.5-3.5 for aortic valve replacements). Deviations can lead to either thromboembolic or bleeding complications.</p>
        <p><bold>Drug interactions:</bold> Warfarin interacts with many medications, foods, and alcohol, making consistent INR control difficult. This requires careful management by patients and healthcare professionals.</p>
        <p><bold>Pregnancy:</bold> Anticoagulation during pregnancy is particularly challenging as warfarin is teratogenic, and alternative anticoagulants like low molecular weight heparin must be used, which requires close monitoring.</p>
      </sec>
      <sec id="article-610.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>MAVR holds significant clinical importance as a life-saving intervention for patients with severe aortic valve disease, particularly aortic stenosis or aortic regurgitation when the native valve becomes dysfunctional. Here's a discussion of its clinical significance:</p>
        <p>
<bold>Durability and Longevity</bold>
</p>
        <p>One of MAVR's primary benefits is the durability of mechanical valves. These prosthetic valves are designed to last several decades, making them particularly advantageous for younger patients with a longer life expectancy. Unlike bioprosthetic valves, which typically last 10 to 20 years, mechanical valves reduce the likelihood of needing repeat surgeries, which carry increased risks.</p>
        <p>
<bold>Restoration of Hemodynamics</bold>
</p>
        <p>MAVR restores normal hemodynamics by replacing a malfunctioning valve, allowing unobstructed blood flow from the left ventricle into the aorta. This improvement alleviates symptoms such as dyspnea, fatigue, angina, and syncope, significantly improving the quality of life and exercise capacity for patients suffering from severe aortic valve disease.</p>
        <p>
<bold>Improved Survival</bold>
</p>
        <p>For patients with severe symptomatic aortic stenosis, untreated disease carries a poor prognosis with high mortality rates. MAVR can dramatically improve survival rates by addressing the underlying cause of heart failure and reducing the risk of sudden cardiac death. This is particularly critical in patients with severe aortic stenosis, where mortality without intervention is approximately 50% within&#x000a0;2 years of symptom onset.</p>
        <p>
<bold>High Risk of Thromboembolism</bold>
</p>
        <p>A significant clinical consideration for MAVR is the lifelong requirement for anticoagulation to prevent thromboembolism. Mechanical valves are highly thrombogenic, and without anticoagulation, patients are at risk for valve thrombosis and systemic embolization, including stroke. This necessitates meticulous management of anticoagulation therapy, typically with warfarin, which must be balanced against the risk of bleeding.</p>
        <p>
<bold>Impact on Patient Selection</bold>
</p>
        <p>The choice of a mechanical valve over a bioprosthetic valve is influenced by several factors, including patient age, lifestyle, and ability to adhere to anticoagulation therapy. Younger patients are generally preferred for MAVR due to the valve's longevity, while older patients or those at higher risk for bleeding may be better suited for a bioprosthetic valve. This decision-making process is critical and involves a multidisciplinary team approach.</p>
        <p>
<bold>Potential for Complications</bold>
</p>
        <p>Despite its benefits, MAVR carries risks such as bleeding, infection, and the potential for prosthetic valve dysfunction. Lifelong anticoagulation increases the risk of major bleeding events, which can be life-threatening. Additionally, mechanical valves can be prone to structural deterioration, though this is rare compared to bioprosthetic valves.</p>
        <p>
<bold>Enhanced Quality of Life</bold>
</p>
        <p>For many patients, MAVR results in significant symptomatic relief and improved quality of life. With the restoration of normal valve function, patients can often return to daily activities and maintain a level of physical exertion previously impossible due to symptoms.</p>
      </sec>
      <sec id="article-610.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective care for patients undergoing mechanical aortic valve replacement (MAVR) requires a multidisciplinary approach involving physicians, advanced clinicians, nurses, pharmacists, and other health professionals. Key skills include technical proficiency in surgical procedures, vigilant monitoring of anticoagulation therapy, and comprehensive patient education. Strategies to enhance care include early identification of potential complications, tailored anticoagulation plans, and regular follow-up.</p>
        <p>Interprofessional communication and care coordination are essential for optimizing outcomes and ensuring patient safety. Physicians and advanced practitioners must collaborate closely with nurses to monitor postoperative recovery and manage anticoagulation therapy, while pharmacists ensure appropriate dosing and educate patients on medication adherence. Clear communication and shared decision-making across the care team enhance patient-centered care, improve clinical outcomes, and bolster team performance, ultimately leading to safer and more effective MAVR procedures.</p>
      </sec>
      <sec id="article-610.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=610&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=610">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/610/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=610">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-610.s13">
        <title>References</title>
        <ref id="article-610.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mechanical and surgical bioprosthetic valve thrombosis.</article-title>
            <source>Heart</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>24</issue>
            <fpage>1934</fpage>
            <page-range>1934-1941</page-range>
            <pub-id pub-id-type="pmid">28780576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eltchaninoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Durand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barbanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdel-Wahab</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>TAVI and valve performance: update on definitions, durability, transcatheter heart valve failure modes and management.</article-title>
            <source>EuroIntervention</source>
            <year>2018</year>
            <month>Aug</month>
            <day>31</day>
            <volume>14</volume>
            <issue>AB</issue>
            <fpage>AB64</fpage>
            <page-range>AB64-AB73</page-range>
            <pub-id pub-id-type="pmid">30158097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Bicuspid aortic valve.</article-title>
            <source>J Insur Med</source>
            <year>2006</year>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-4</page-range>
            <pub-id pub-id-type="pmid">16642647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunihara</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Anatomy of the aortic root: implications for aortic root reconstruction.</article-title>
            <source>Gen Thorac Cardiovasc Surg</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>488</fpage>
            <page-range>488-499</page-range>
            <pub-id pub-id-type="pmid">28656518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouma</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>van Den Brink</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>van Der Meulen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Verheul</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Cheriex</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hamer</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Dekker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>To operate or not on elderly patients with aortic stenosis: the decision and its consequences.</article-title>
            <source>Heart</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-8</page-range>
            <pub-id pub-id-type="pmid">10409526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thaden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nkomo</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Enriquez-Sarano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The global burden of aortic stenosis.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>565</fpage>
            <page-range>565-71</page-range>
            <pub-id pub-id-type="pmid">24838132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Aortic stenosis.</article-title>
            <source>Circulation</source>
            <year>1968</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>1 Suppl</issue>
            <fpage>61</fpage>
            <page-range>61-7</page-range>
            <pub-id pub-id-type="pmid">4894151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Tuzcu</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Makkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Pichard</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bavaria</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>S</given-names>
              </name>
              <collab>PARTNER Trial Investigators</collab>
            </person-group>
            <article-title>Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Oct</month>
            <day>21</day>
            <volume>363</volume>
            <issue>17</issue>
            <fpage>1597</fpage>
            <page-range>1597-607</page-range>
            <pub-id pub-id-type="pmid">20961243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thourani</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Forcillo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szeto</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Kodali</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Blackstone</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Lowry</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Semple</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rajeswaran</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Makkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bavaria</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Maniar</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Babaliaros</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Trento</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corso</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Pichard</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ailawadi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Greason</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Jaber</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Alu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>PARTNER Trial Investigators</collab>
            </person-group>
            <article-title>Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical Aortic Valve Replacement in PARTNER-2A.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2018</year>
            <month>May</month>
            <volume>105</volume>
            <issue>5</issue>
            <fpage>1322</fpage>
            <page-range>1322-1329</page-range>
            <pub-id pub-id-type="pmid">29253463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumgartner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bermejo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Edvardsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>LeFevre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.</article-title>
            <source>Eur Heart J Cardiovasc Imaging</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-275</page-range>
            <pub-id pub-id-type="pmid">28363204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Skubas</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology</collab>
              <collab>American College of Cardiology/American Heart Association</collab>
              <collab>American Heart Association</collab>
            </person-group>
            <article-title>2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e132</page-range>
            <pub-id pub-id-type="pmid">24939033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Rigolin</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular&#x000a0;Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>11</day>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-289</page-range>
            <pub-id pub-id-type="pmid">28315732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Rigolin</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toly</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2021</year>
            <month>Feb</month>
            <day>02</day>
            <volume>143</volume>
            <issue>5</issue>
            <fpage>e35</fpage>
            <page-range>e35-e71</page-range>
            <pub-id pub-id-type="pmid">33332149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumgartner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lansac</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rodriguez Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenhek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;gren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tornos Mas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vahanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wendler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2017 ESC/EACTS Guidelines for the management of valvular heart disease.</article-title>
            <source>Eur Heart J</source>
            <year>2017</year>
            <month>Sep</month>
            <day>21</day>
            <volume>38</volume>
            <issue>36</issue>
            <fpage>2739</fpage>
            <page-range>2739-2791</page-range>
            <pub-id pub-id-type="pmid">28886619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>132</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-6</page-range>
            <pub-id pub-id-type="pmid">16798297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashikhmina</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Schaff</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Dearani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Burkhart</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Aortic valve replacement in the elderly: determinants of late outcome.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Aug</month>
            <day>30</day>
            <volume>124</volume>
            <issue>9</issue>
            <fpage>1070</fpage>
            <page-range>1070-8</page-range>
            <pub-id pub-id-type="pmid">21824918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Skubas</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JD</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>10</day>
            <volume>63</volume>
            <issue>22</issue>
            <fpage>e57</fpage>
            <page-range>e57-185</page-range>
            <pub-id pub-id-type="pmid">24603191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fatehi Hassanabad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vasanthan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>WDT</given-names>
              </name>
            </person-group>
            <article-title>Minimally Invasive Surgical Aortic Valve Replacement: An Overview of Recent Advances.</article-title>
            <source>Can J Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-228</page-range>
            <pub-id pub-id-type="pmid">30760431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Onofrio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rizzoli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alfieri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lorusso</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salizzoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glauber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Bartolomeo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Besola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Troise</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gerosa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Conventional surgery, sutureless valves, and transapical aortic valve replacement: what is the best option for patients with aortic valve stenosis? A multicenter, propensity-matched analysis.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>146</volume>
            <issue>5</issue>
            <fpage>1065</fpage>
            <page-range>1065-70; discussion 1070-1</page-range>
            <pub-id pub-id-type="pmid">24021955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarride</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Luong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goodall</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blackhouse</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients.</article-title>
            <source>Clinicoecon Outcomes Res</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>477</fpage>
            <page-range>477-486</page-range>
            <pub-id pub-id-type="pmid">31551658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rajput</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Zeltser</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Aortic Valve Replacement</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30725821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-610.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mid- to long-term outcome comparison of the Medtronic Hancock II and bi-leaflet mechanical aortic valve replacement in patients younger than 60 years of age: a propensity-matched analysis.</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-6</page-range>
            <pub-id pub-id-type="pmid">26675564</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
